<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">39394252</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>11</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>17</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>11</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>Side effects associated with homogenous and heterogenous doses of Oxford-AstraZeneca vaccine among adults in Bangladesh: an observational study.</ArticleTitle><Pagination><StartPage>23794</StartPage><MedlinePgn>23794</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">23794</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-024-75833-z</ELocationID><Abstract><AbstractText>Assessment of side effects associated with COVID-19 vaccination is required to monitor safety issues and acceptance of vaccines in the long term. We found a significant knowledge gap in the safety profile of COVID-19 vaccines in Bangladesh. We enrolled 1805 vaccine recipients from May 5, 2021, to April 4, 2023. Kruskal-Wallis test and χ2 test were performed. Multivariable logistic regression was also performed. First, second and third doses were administered among 1805, 1341, and 923 participants, respectively. Oxford-AstraZeneca (2946 doses) was the highest administered followed by Sinopharm BIBP (551 doses), Sinovac (214 doses), Pfizer-BioNTech (198 doses), and Moderna (160 doses), respectively. Pain at the injection site (80-90%, 3200-3600), swelling (85%, 3458), redness (78%, 3168), and heaviness in hand (65%, 2645) were the most common local effects, and fever (85%, 3458), headache (82%, 3336), myalgia (70%, 2848), chills (67%, 2726), muscle pain (60%, 2441) were the most prevalent systemic side effects reported within 48 h of vaccination. Thrombosis was only reported among the Oxford-AstraZeneca recipients (3.5-5.7%). Both local and systemic effects were significantly associated with the Oxford-AstraZeneca (p-value &lt; 0.05), Pfizer-BioNTech (p-value &lt; 0.05), and Moderna (p-value &lt; 0.05) vaccination. Chronic urticaria and psoriasis were reported by 55-60% of the recipients after six months or later. The highest percentage of local and systemic effects after 2nd and 3rd dose were found among recipients of Moderna followed by Pfizer-BioNTech and Oxford-AstraZeneca. Homogenous doses of Oxford-AstraZeneca and heterogenous doses of Moderna and Pfizer-BioNTech were significantly associated with elevated adverse effects. Females, aged above 60 years with preexisting health conditions had higher risks. Vaccination with Pfizer-BioNTech (OR 4.34, 95% CI 3.95-4.58) had the highest odds of severe and long-term effects followed by Moderna (OR 4.15, 95% CI 3.92-4.69) and Oxford-AstraZeneca (OR 3.89, 95% CI 3.45-4.06), respectively. This study will provide an integrated insight into the safety profile of COVID-19 vaccines.</AbstractText><CopyrightInformation>© 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sharif</LastName><ForeName>Nadim</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Microbiology, Jahangirnagar University, Savar, Dhaka-1342, Savar, Dhaka, 1342, Bangladesh. nadim@juniv.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Opu</LastName><ForeName>Rubayet Rayhan</ForeName><Initials>RR</Initials><AffiliationInfo><Affiliation>Department of Microbiology, Jahangirnagar University, Savar, Dhaka-1342, Savar, Dhaka, 1342, Bangladesh.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saha</LastName><ForeName>Tama</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Microbiology, Jahangirnagar University, Savar, Dhaka-1342, Savar, Dhaka, 1342, Bangladesh.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khan</LastName><ForeName>Afsana</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Statistics and Data Science, Jahangirnagar University, Savar, Dhaka, 1342, Bangladesh.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aljohani</LastName><ForeName>Abrar</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Clinical Laboratories Sciences, College of Applied Medical Sciences, Taif University, P.O. Box 11099, Taif, 21944, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alsuwat</LastName><ForeName>Meshari A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Department of Clinical Laboratories Sciences, College of Applied Medical Sciences, Taif University, P.O. Box 11099, Taif, 21944, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>García</LastName><ForeName>Carlos O</ForeName><Initials>CO</Initials><AffiliationInfo><Affiliation>Universidad Europea del Atlántico, Isabel Torres 21, Santander, 39011, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Universidad Internacional Iberoamericana, Campeche, 24560, México.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vázquez</LastName><ForeName>Annia A</ForeName><Initials>AA</Initials><AffiliationInfo><Affiliation>Universidad Europea del Atlántico, Isabel Torres 21, Santander, 39011, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Universidad Internacional Iberoamericana, Campeche, 24560, México.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Universidad de La Romana, La Romana, República Dominicana.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alzahrani</LastName><ForeName>Khalid J</ForeName><Initials>KJ</Initials><AffiliationInfo><Affiliation>Department of Clinical Laboratories Sciences, College of Applied Medical Sciences, Taif University, P.O. Box 11099, Taif, 21944, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miramontes-González</LastName><ForeName>J Pablo</ForeName><Initials>JP</Initials><AffiliationInfo><Affiliation>Facultad de Medicina. Departamento de Medicina, University of Valladolid, Valladolid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dey</LastName><ForeName>Shuvra Kanti</ForeName><Initials>SK</Initials><AffiliationInfo><Affiliation>Department of Microbiology, Jahangirnagar University, Savar, Dhaka-1342, Savar, Dhaka, 1342, Bangladesh. shuvradey@yahoo.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>B5S3K2V0G8</RegistryNumber><NameOfSubstance UI="D000090985">ChAdOx1 nCoV-19</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001459" MajorTopicYN="N" Type="Geographic">Bangladesh</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="N">COVID-19 Vaccines</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006261" MajorTopicYN="N">Headache</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000090985" MajorTopicYN="N">ChAdOx1 nCoV-19</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Bangladesh</Keyword><Keyword MajorTopicYN="N">Heterogenous</Keyword><Keyword MajorTopicYN="N">Long-term</Keyword><Keyword MajorTopicYN="N">Side effects, COVID-19 vaccines</Keyword></KeywordList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>6</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>12</Day><Hour>9</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>12</Day><Hour>9</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>11</Day><Hour>23</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>11</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39394252</ArticleId><ArticleId IdType="pmc">PMC11470050</ArticleId><ArticleId IdType="doi">10.1038/s41598-024-75833-z</ArticleId><ArticleId IdType="pii">10.1038/s41598-024-75833-z</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Mathieu, E. et al. Coronavirus pandemic (COVID-19). Our world in data. (2024). https://ourworldindata.org/coronavirus</Citation></Reference><Reference><Citation>COVID - Coronavirus Statistics. Worldometers. (2024). https://www.worldometers.info/coronavirus/</Citation></Reference><Reference><Citation>World Health Organization (WHO). (2024). https://www.who.int/emergencies/diseases/novel-coronavirus-2019/covid-19-vaccines</Citation></Reference><Reference><Citation>List of Prequalified Vaccines. World Health Organization (WHO). (2024). https://extranet.who.int/prequal/vaccines/list-prequalified-vaccines</Citation></Reference><Reference><Citation>Sharif, N., Alzahrani, K. J., Ahmed, S. N. &amp; Dey, S. K. Efficacy, immunogenicity and safety of COVID-19 vaccines: a systematic review and meta-analysis. Front. Immunol. 12, 714170 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8542872</ArticleId><ArticleId IdType="pubmed">34707602</ArticleId></ArticleIdList></Reference><Reference><Citation>COVID-19 Vaccination Dashboard for Bangladesh. (2024). https://dashboard.dghs.gov.bd/pages/covid19-vaccination-update.php</Citation></Reference><Reference><Citation>Mushtaq, H. A. et al. A review of adverse effects of COVID-19 vaccines. Le Infezioni Med. 30, 1 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8929726</ArticleId><ArticleId IdType="pubmed">35350266</ArticleId></ArticleIdList></Reference><Reference><Citation>Beatty, A. L. et al. Analysis of COVID-19 vaccine type and adverse effects following vaccination. JAMA Netw. open. 4, 2140364–2140364 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8696570</ArticleId><ArticleId IdType="pubmed">34935921</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharif, N. et al. Protective measures are associated with the reduction of transmission of COVID-19 in Bangladesh: a nationwide cross-sectional study. PLoS One. 16, e0260287 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8608304</ArticleId><ArticleId IdType="pubmed">34807962</ArticleId></ArticleIdList></Reference><Reference><Citation>McDonald, I., Murray, S. M., Reynolds, C. J., Altmann, D. M. &amp; Boyton, R. J. Comparative systematic review and meta-analysis of reactogenicity, immunogenicity and efficacy of vaccines against SARS-CoV-2. npj Vaccines. 6, 74 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8116645</ArticleId><ArticleId IdType="pubmed">33986272</ArticleId></ArticleIdList></Reference><Reference><Citation>Patwary, M. M. et al. COVID-19 vaccine acceptance among low-and lower-middle-income countries: a rapid systematic review and meta-analysis. Vaccines. 10, 427 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8950670</ArticleId><ArticleId IdType="pubmed">35335059</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, J. et al. Acceptance of COVID-19 vaccination during the COVID-19 pandemic in China. Vaccines. 8, 482 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7565574</ArticleId><ArticleId IdType="pubmed">32867224</ArticleId></ArticleIdList></Reference><Reference><Citation>Shakeel, C. S., Mujeeb, A. A., Mirza, M. S., Chaudhry, B. &amp; Khan, S. J. Global COVID-19 vaccine acceptance: a systematic review of associated social and behavioral factors. Vaccines. 10, 110 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8779795</ArticleId><ArticleId IdType="pubmed">35062771</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaplan, R. M. &amp; Milstein, A. Influence of a COVID-19 vaccine’s effectiveness and safety profile on vaccination acceptance. Proc. Natl. Acad. Sci. 118, e2021726118 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7958192</ArticleId><ArticleId IdType="pubmed">33619178</ArticleId></ArticleIdList></Reference><Reference><Citation>Majeed, A., Papaluca, M. &amp; Molokhia, M. Assessing the long-term safety and efficacy of COVID-19 vaccines. J. Roy Soc. Med. 114, 337–340 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8276333</ArticleId><ArticleId IdType="pubmed">33945346</ArticleId></ArticleIdList></Reference><Reference><Citation>Sendra, A., Torkkola, S. &amp; Parviainen, J. AstraZeneca vaccine controversies in the media: theorizing about the mediatization of ignorance in the context of the COVID-19 vaccination campaign. Health Commun. 39, 541–551 (2024).</Citation><ArticleIdList><ArticleId IdType="pubmed">36703490</ArticleId></ArticleIdList></Reference><Reference><Citation>Mirnia, K. et al. Short-term side effects of COVID-19 vaccines among healthcare workers: a multicenter study in Iran. Sci. Rep. 14, 4086 (2024).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10876545</ArticleId><ArticleId IdType="pubmed">38374372</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen, S. V. et al. Side effects following first dose of COVID-19 vaccination in Ho Chi Minh City, Vietnam. Hum. Vaccines Immunother. 21760 66 (2023). (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10026889</ArticleId><ArticleId IdType="pubmed">36856074</ArticleId></ArticleIdList></Reference><Reference><Citation>Alhazmi, A. et al. Evaluation of side effects associated with COVID-19 vaccines in Saudi Arabia. Vaccines. 9, 674 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8235009</ArticleId><ArticleId IdType="pubmed">34207394</ArticleId></ArticleIdList></Reference><Reference><Citation>Ganesan, S. et al. Vaccine side effects following COVID-19 vaccination among the residents of the UAE—an observational study. Front. Public. Health. 10, 876336 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9120526</ArticleId><ArticleId IdType="pubmed">35602146</ArticleId></ArticleIdList></Reference><Reference><Citation>Arora, G. et al. Adverse events and breakthrough infections associated with COVID-19 vaccination in the Indian population. J. Med. Virol. 94, 3147–3154 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9088477</ArticleId><ArticleId IdType="pubmed">35261064</ArticleId></ArticleIdList></Reference><Reference><Citation>Chakraborty, A., Reval, N. &amp; Kamath, L. Adverse events following COVID-19 vaccination in selected apartments in Bangalore, India. Cureus. 14, e21809 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8896841</ArticleId><ArticleId IdType="pubmed">35291520</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohsin, M. et al. Side effects of COVID-19 vaccines and perceptions about COVID-19 and its vaccines in Bangladesh: a cross-sectional study. Vaccine: X. 12, 100207 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9394094</ArticleId><ArticleId IdType="pubmed">36032698</ArticleId></ArticleIdList></Reference><Reference><Citation>Seyed Alinaghi, S. et al. Safety and adverse events related to COVID-19 mRNA vaccines; a systematic review. Arch. acad. Emerg. med. 10, e41 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9206826</ArticleId><ArticleId IdType="pubmed">35765616</ArticleId></ArticleIdList></Reference><Reference><Citation>Aldali, J., Meo, S. A. &amp; Al-Khlaiwi, T. Adverse effects of Pfizer (BioNTech), Oxford-AstraZeneca (ChAdOx1 CoV-19), and Moderna COVID-19 vaccines among the adult population in Saudi Arabia: a cross-sectional study. Vaccines. 11, 231 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9967558</ArticleId><ArticleId IdType="pubmed">36851109</ArticleId></ArticleIdList></Reference><Reference><Citation>Judd, A. et al. Urticaria after COVID-19 vaccination and vaccine hesitancy. J. Allergy Clin. Immunol. Pract. 11, 958 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9791784</ArticleId><ArticleId IdType="pubmed">36581074</ArticleId></ArticleIdList></Reference><Reference><Citation>Ben-Fredj, N. et al. Case series of chronic spontaneous urticaria following COVID-19 vaccines: an unusual skin manifestation. Eur. J. Clin. Pharmacol. 78, 1959–1964 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9579615</ArticleId><ArticleId IdType="pubmed">36255482</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu, P. C. et al. New onset and exacerbations of psoriasis following COVID-19 vaccines: a systematic review. Am. J. Clin. Dermatol. 23, 775–799 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9434078</ArticleId><ArticleId IdType="pubmed">36048409</ArticleId></ArticleIdList></Reference><Reference><Citation>Wulandari, P. K. et al. Adverse effects of Third-Dose Moderna Vaccination for Healthcare Workers of Udayana University Hospital, Bali, Indonesia. Int. J. Med. Stud. 10, S165–S165 (2022).</Citation></Reference><Reference><Citation>Tobaiqy, M., MacLure, K., Elkout, H. &amp; Stewart, D. Thrombotic adverse events reported for Moderna, Pfizer and Oxford-AstraZeneca COVID-19 vaccines: comparison of occurrence and clinical outcomes in the EudraVigilance database. Vaccines. 9, 1326 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8624459</ArticleId><ArticleId IdType="pubmed">34835256</ArticleId></ArticleIdList></Reference><Reference><Citation>Babaee, E. et al. Adverse effects following COVID-19 vaccination in Iran. BMC Infect. Dis. 22, 476 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9116064</ArticleId><ArticleId IdType="pubmed">35585518</ArticleId></ArticleIdList></Reference><Reference><Citation>Pottegård, A. et al. Arterial events, venous thromboembolism, thrombocytopenia, and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population based cohort study. Bmj. 373, n1114 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8097496</ArticleId><ArticleId IdType="pubmed">33952445</ArticleId></ArticleIdList></Reference><Reference><Citation>Wise, J. Covid-19: European countries suspend use of Oxford-AstraZeneca vaccine after reports of blood clots. Bmj. 372, n699 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33707182</ArticleId></ArticleIdList></Reference><Reference><Citation>Favas, T. T. et al. Thrombotic and thromboembolic complications after vaccination against COVID-19: a systematic review. Cureus. 15, e37275 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10167937</ArticleId><ArticleId IdType="pubmed">37182082</ArticleId></ArticleIdList></Reference><Reference><Citation>Østergaard, S. D., Schmidt, M., Horváth-Puhó, E., Thomsen, R. W. &amp; Sørensen, H. T. Thromboembolism and the Oxford–AstraZeneca COVID-19 vaccine: side-effect or coincidence? Lancet. 397, 1441–1443 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8009607</ArticleId><ArticleId IdType="pubmed">33798498</ArticleId></ArticleIdList></Reference><Reference><Citation>John, C. V. et al. Vaccine-induced thrombotic thrombocytopenia (VITT): first report from India. Thromb. J. 20, 11 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8894558</ArticleId><ArticleId IdType="pubmed">35246163</ArticleId></ArticleIdList></Reference><Reference><Citation>Menni, C. et al. Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study. Lancet Infect. Dis. 21, 939–949 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8078878</ArticleId><ArticleId IdType="pubmed">33930320</ArticleId></ArticleIdList></Reference><Reference><Citation>Menni, C. et al. COVID-19 vaccine waning and effectiveness and side-effects of boosters: a prospective community study from the ZOE COVID Study. Lancet Infect. Dis. 22, 1002–1010 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8993156</ArticleId><ArticleId IdType="pubmed">35405090</ArticleId></ArticleIdList></Reference><Reference><Citation>Dighriri, I. M. et al. Pfizer-BioNTech COVID-19 vaccine (BNT162b2) side effects: a systematic review. Cureus. 14, e23526 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9039171</ArticleId><ArticleId IdType="pubmed">35494952</ArticleId></ArticleIdList></Reference><Reference><Citation>Elgendy, M. O. et al. Side effects and efficacy of COVID-19 vaccines among the Egyptian population. Vaccines. 10, 109 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8779934</ArticleId><ArticleId IdType="pubmed">35062770</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan, F. et al. Side effects of COVID-19 vaccines among diabetic subjects and healthy individuals. Cureus. 15, e36005 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10083655</ArticleId><ArticleId IdType="pubmed">37041898</ArticleId></ArticleIdList></Reference><Reference><Citation>d’Almeida, S. et al. Thromboembolism after Astra Zeneca COVID-19 vaccine: not always PF4-antibody mediated. Hum. Vaccines Immunother. 19, 2252239 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10478733</ArticleId><ArticleId IdType="pubmed">37655367</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharif, N. et al. Prevalence and impact of long COVID-19 among patients with diabetes and cardiovascular diseases in Bangladesh. Front. Public. Health. 11, 1222868 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10641795</ArticleId><ArticleId IdType="pubmed">37965507</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharif, N. et al. Prevalence and impact of comorbidities on disease prognosis among patients with COVID-19 in Bangladesh: a nationwide study amid the second wave. Diabetes Metab. Syndr. Clin. Res. Rev. 15, 102148 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8236060</ArticleId><ArticleId IdType="pubmed">34186349</ArticleId></ArticleIdList></Reference><Reference><Citation>Guidance for industry. Toxicity grading scale for healthy adult and adolescent volunteers enrolled in preventive vaccine clinical trials. (2021). https://www.fda.gov/media/73679/download</Citation><ArticleIdList><ArticleId IdType="pubmed">37532612</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>